This document provides disclosure information for John R. Teerlink, the presenter of a study on intravenous omecamtiv mecarbil in patients with acute heart failure. It notes that Dr. Teerlink has received research funding from Amgen, the sponsor of the study, and has consulting fees from several other companies. It also states that the use of omecamtiv mecarbil is investigational. The technical support of Karen Driver, who was also supported by Amgen, is acknowledged.

1. Presenter Disclosure Information
John R. Teerlink, M.D., F.A.C.C., F.A.H.A., F.E.S.C., F.R.C.P.
Professor of Medicine, University of California San Francisco
Director of Heart Failure, San Francisco Veterans Affairs Medical Center
• Financial Disclosure
– This study was funded by Amgen Inc.
– J.R. Teerlink has received research grants and/or consulting fees from
Amgen, Corthera, Cytokinetics, Merck, Novartis, Sorbent, and Trevena
• Unlabeled/unapproved uses disclosure
– Use of omecamtiv mecarbil in patients with heart failure is investigational.
• The technical support of Karen Driver is acknowledged and was supported by Amgen Inc.
UCSF

2. A Phase 2 Study of
Intravenous Omecamtiv Mecarbil,
A Novel Cardiac Myosin Activator,
In Patients With Acute Heart Failure
John R. Teerlink, G. Michael Felker, John J. V. McMurray,
Piotr Ponikowski, Marco Metra, Gerasimos S. Filippatos,
Kenneth Dickstein, Justin A. Ezekowitz, John G. Cleland,
Jae B. Kim, Lei Lei, Beat Knusel, Andrew A. Wolff,
Fady I. Malik and Scott M. Wasserman
on behalf of the ATOMIC-AHF Investigators and Patients

3. Omecamtiv Mecarbil (OM) is a Novel
Selective Cardiac Myosin Activator
Malik FI, et al. Science 2011; 331:1439-43.
Mechanochemical Cycle of Myosin
Force production
Omecamtiv mecarbil increases the
entry rate of myosin into the
tightly-bound, force-producing
state with actin
“More hands pulling on the rope”

4. Increases in Systolic Ejection Time
Underlie Increases in Cardiac Function
Δ Stroke Volume
(mL)
Δ Fractional Shortening
(% points)
Δ Ejection Fraction
(% points)
Δ = placebo corrected
change from baseline
Mean ± SEM
300 600 900 1200
-80
-40
0
40
80
120
160
Healthy Volunteers vs. Heart Failure Patients
SET Heart Failure
SET Healthy Volunteers
[Omecamtiv mecarbil] (ng/mL)
SET(msec)
ChangefromBaseline
Δ SET (msec)
Cleland JGF, et al. Lancet 2011; 378: 676–83.
Teerlink JR, et al. Lancet 2011; 378: 667–75.
Healthy Volunteers

5. Objective:
•To evaluate the safety, pharmacokinetics/ pharmacodynamics,
and efficacy of IV omecamtiv mecarbil (OM) in patients with acute
heart failure (AHF)
Hypothesis:
•At least 1 dose level of IV OM will be well tolerated and will result
in improvement of dyspnoea in subjects with left ventricular
systolic dysfunction hospitalised for AHF
ATOMIC-AHF
Acute Treatment with Omecamtiv Mecarbil to
Increase Contractility in Acute Heart Failure

6. Study Design: Sequential Dosing Cohort
Cohort 1 Cohort 2 Cohort 3
Omecamtiv
Placebo
1:1 Randomization (n≈200)
Omecamtiv
Placebo
1:1 randomization (n≈200)
Placebo
Omecamtiv
1:1 randomization (n≈200)
DMC DMC
Cohort 1 Cohort 2 Cohort 3
15 mg/hr @ 0-4 hr
3 mg/hr @ 4-48 hr
Target: 230 ng/mL
Cmax: 75-500 ng/mL
SET: ~8-55 msec
20 mg/hr @ 0-4 hr
4 mg/hr @ 4-48 hr
Target: 310 ng/mL
Cmax: 125-700 ng/mL
SET: ~14-78 msec
7.5 mg/hr @ 0-4 hr
1.5 mg/hr @ 4-48 hr
Target: 115 ng/mL
Cmax: 30-250 ng/mL
SET: ~3-28 msec
Pharmacokinetic simulations
Teerlink JR, et al. Lancet 2011; 378: 667–75; Cleland JGF, et al. Lancet 2011; 378: 676–83.

7. Study Design
Placebo IVPlacebo IV
0 72484Time (hrs)
M A N D A T O R Y I N - H O S P I T A L S T A YM A N D A T O R Y I N - H O S P I T A L S T A Y
Day 30
EOSLoading
Dose
Omecamtiv mecarbil IVOmecamtiv mecarbil IV
Month 6
* Randomisation within 24 hours of initial IV diuretic (Amendment 2)
Randomised, double-blind, placebo-controlled,
sequential cohort study
6 15 24 Day 6/
DC
Study drug administration
1⁰ EP dyspnoea response
PK sampling
all subjects
PK/PD sub-study
Echo (PK/PD sub-study)
Maintenance
Dose
96
Cardiac troponin/CK-MB

8. Key Inclusion and Exclusion Criteria
Key Inclusion Criteria
•Male/female ≥ 18 and ≤ 85 y
•History of HF and LVEF ≤40%
•Hospitalised for AHF requiring IV
therapy
•Dyspnoea due to HF at rest or
with minimal exertion ≥2 hours
after iv diuretic
•Screening BNP ≥ 400 pg/mL or
NT-proBNP ≥ 1600 pg/mL
(BNP ≥ 600 pg/mL or NT-proBNP
≥2400 pg/mL, if the subject has
atrial fibrillation)
Key Exclusion Criteria
•Receiving IV vasopressor, inotropic
or mechanical support
•Acute coronary syndrome (ACS) on
presentation
•Recent vascular event or cardiac
procedure
•Severe obstructive valvular or
myocardial disease
•BP >160/100 or SBP <90 mmHg, or
HR >110 or <60 bpm
•eGFR (MDRD) <20 mL/min/1.73m2
Randomised within 24 hours of initial IV diuretic treatment

9. Primary:
•Dyspnoea symptom response (7-point Likert scale) through 48 hours
Secondary:
•Death (any cause) and/or worsening heart failure within 7 days
•Dyspnoea area under the curve (AUC) (baseline to 5th
day or discharge) as
measured by subject self-assessed Numerical Rating Scale (NRS)
•Dyspnoea by 7-point Likert scale at each scheduled assessment
•Patient Global Assessment response through 48 hours
•Change from baseline in NT-proBNP
•Length of initial hospital stay
•Days alive out of hospital until day 30
PK/PD (Echo) Sub-study
Efficacy Endpoints

10. Characteristic
Pooled
Placebo
(N = 303)
Cohort 1
OM
(N = 103)
Cohort 2
OM
(N = 99)
Cohort 3
OM
(N = 101)
Age , mean (SD) 66 (11) 65 (12) 67 (10) 68 (10)
Gender – male, % 76 76 82 76
Region, % *
Eastern Europe 53 45 56 62
North America 25 37 24 18
Australia 2 0 1 0
Western Europe 21 18 19 20
Ischaemic heart disease, % 62 62 59 66
Years from HF diagnosis, mean (SD) 6 (6) 6 (6) 6 (5) 6 (5)
Most recent LVEF (%), mean (SD) 26 (8) 26 (8) 25 (7) 28 (7)
Persistent Atrial Fibrillation or Flutter, % 33 29 32 36
Diabetes Mellitus, % 45 49 41 42
Hypertension, % 81 84 81 82
Baseline Characteristics (1)
*
p < 0.05 for a difference in cohorts 1-3 Placebo arms compared to each other

11. Characteristic
Pooled
Placebo
(N = 303)
Cohort 1
OM
(N = 103)
Cohort 2
OM
(N = 99)
Cohort 3
OM
(N = 101)
Systolic BP (mmHg), mean (SD) 119 (18)* 118 (18) 117 (17) 117 (15)
Heart rate (beats/min), mean (SD) 78 (13) 78 (13) 79 (13) 78 (14)
Dyspnoea Numerical Rating Scale (NRS), Mean (SD) 6 (2) 6 (2) 6 (2) 6 (2)
ACE inhibitors/Angiotensin Receptor Blockers, % 78 79 74 84
Beta blocker, % 86* 90 87 90
Digoxin, % 20 28 26 22
Mineralocorticoid Receptor Antagonist, % 55 54 59 58
Ivabradine, % 3 4 4 6
Troponin-I, median (URL 0.04 ng/mL) 0.044* 0.060 0.044 0.056
NT-proBNP (pg/mL), median 9026 7674 10488 10416
eGFR (mL/min/1.73m2
), mean (SD) 53 (18)* 52 (18) 53 (19) 50 (18)
Time from presentation to randomisation, mean (SD) 15 (8)* 12 (8) 16 (10) 15 (9)
Baseline Characteristics (2)
*
p < 0.05 for a difference in cohorts 1-3 Placebo arms compared to each other;
URL= upper reference limit

12. Responder defined as:
•Minimally, moderately or markedly better at 6 hours
AND
•Moderately or markedly better at both 24 and 48 hours
WITHOUT
•Worsening heart failure or death for any cause
by 48 hours
Primary Efficacy Endpoint
Dyspnoea Response (Likert Scale)

13. Primary Efficacy Endpoint:
Dyspnoea Response (Likert Scale)
Pooled Placebo
Response Rate
Ratio*
1.03 1.15 1.23
95% CI (0.79, 1.35) (0.90, 1.47) (0.97, 1.55)
*Ratio of response rate to Pooled Placebo
p-value of a CMH test among all 3 Placebo arms = 0.32
Overall p-value = 0.33
Pooled
Placebo
OM
Cohort 1
OM
Cohort 2
OM
Cohort 3
DyspnoeaResponseRate
(%Responders)
0
5
10
15
20
25
30
35
40
45
50
55
42%
47%
51%
41%

14. Supplemental Primary Analysis:
Dyspnoea Response (Likert Scale)
Paired Placebo
Response
Rate Ratio
1.02 1.02 1.41
95% CI (0.74, 1.42) (0.76, 1.37) (1.02, 1.93)
Response rate ratio: ratio of response rate to Placebo within each cohort
Cohort 1
OM OM OM
42%41%
Cohort 2
47%46%
Cohort 3
Placebo
51%
37%
DyspnoeaResponseRate
(%Responders)
0
5
10
15
20
25
30
35
40
45
50
55
PlaceboPlacebo
p = NS
p = NS
p = 0.03

15. For Increases
of…
Response Rate
Ratio
Increases… 95% CI P-value
Dose*
50 mg total OM
administered
5.5% 0.7% – 10.6% 0.025
Plasma
concentration*
4000 hr*ng/mL
AUC48h
6.4% 1.7% – 11.4% 0.007
Exploratory Analyses: Dose and Concentration
Relationship to Dyspnoea Response
* Adjusted for region, cohort, age, baseline NRS, presentation-randomisation duration (continuous)

16. Within 7 days of IP initiation
Pooled
Placebo
(N = 303)
Cohort 1
OM
(N = 103)
Cohort 2
OM
(N = 99)
Cohort 3
OM
(N = 101)
Death or WHF*
Yes - n(%) 52 (17) 13 (13) 9 (9) 9 (9)
Relative risk 0.67 0.54 0.54
(95% CI) (0.38, 1.18) (0.28, 1.04) (0.27, 1.08)
p-value 0.151 0.054 0.067
WHF*
Yes - n(%) 51 (17) 13 (13) 8 (8) 9 (9)
Relative risk 0.68 0.49 0.55
(95% CI) (0.38, 1.21) (0.24, 0.98) (0.28, 1.09)
p-value 0.179 0.034 0.075
Secondary Efficacy Endpoint:
Worsening Heart Failure (WHF)
*Worsening heart failure is defined as clinical evidence of persistent or deteriorating
heart failure requiring at least one of the following treatments:
•Initiation, reinstitution or intensification of IV vasodilator
•Initiation of IV positive inotropes, or IV vasopressors
•Initiation of ultrafiltration, hemofiltration, or dialysis
•Initiation of mechanical ventilatory or circulatory support

17. Pooled
Placebo
(N = 303)
Cohort 1
OM
(N = 103)
Cohort 2
OM
(N = 99)
Cohort 3
OM
(N = 101)
Dyspnoea Numerical Response AUC
through Day 6, mean (95% CI)
3.5
(3.3, 3.8)
3.5
(3.1, 3.9)
3.6
(3.2, 4.0)
3.7
(3.3, 4.0)
Patient Global Assessment response,
n (%)
127
(42)
44
(43)
48
(48)
51
(50)
Length of initial hospital stay,
median days (95% CI)
9
(8, 9)
8
(7, 9)
7
(7, 8)
9
(8, 10)
Days alive out of hospital through
30 days, median (95% CI)
22
(21, 23)
23
(21, 24)
23
(23, 24)
22
(21, 23)
NT-proBNP change from BL (pg/mL)
at 48 hours, median (95% CI)
-1805
(-2271, -1370)
-2076
(-2746, -1292)
-2161
(-4273, -1336)
-1742
(-2517, -1017)
Other Secondary Efficacy Endpoints
All comparisons to Pooled Placebo not significant (p > 0.05)

18. Preferred Term
Patient Incidence, n (%)
Pooled
Placebo
(N = 303)
Pooled
OM
(N = 303)
Cohort 1
OM
(N = 103)
Cohort 2
OM
(N = 99)
Cohort 3
OM
(N = 101)
Number of subjects reporting AEs of
Supraventricular or Ventricular
Tachyarrhythmia
34 (11.2) 26 (8.6) 13 (12.6) 5 (5.1) 8 (7.9)
Supraventricular Tachyarrhythmias 20 (6.6) 10 (3.3) 6 (5.8) 0 (0.0) 4 (4.0)
Atrial Fibrillation or Atrial Flutter 15 (5.0) 6 (2.0) 3 (2.9) 0 (0.0) 3 (3.0)
Atrial Tachycardia 3 (1.0) 1 (0.3) 1 (1.0) 0 (0.0) 0 (0.0)
Sinus Tachycardia 1 (0.3) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Supraventricular Tachycardia 2 (0.7) 4 (1.3) 3 (2.9) 0 (0.0) 1 (1.0)
Ventricular Tachyarrhythmias 18 (5.9) 17 (5.6) 8 (7.8) 5 (5.1) 4 (4.0)
Ventricular Arrhythmia 4 (1.3) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Ventricular Extrasystoles 1 (0.3) 2 (0.7) 1 (1.0) 1 (1.0) 0 (0.0)
Ventricular Fibrillation 2 (0.7) 1 (0.3) 0 (0.0) 1 (1.0) 0 (0.0)
Ventricular Tachyarrhythmia 0 (0.0) 1 (0.3) 1 (1.0) 0 (0.0) 0 (0.0)
Ventricular Tachycardia 11 (3.6) 13 (4.3) 7 (6.8) 3 (3.0) 3 (3.0)
Extrasystoles 0 (0.0) 1 (0.3) 0 (0.0) 0 (0.0) 1 (1.0)
Supraventricular and Ventricular
Tachyarrhythmias

19. Patient Incidence, n (%)
Pooled
Placebo
(N = 303)
Pooled
OM
(N = 303)
Cohort 1
OM
(N = 103)
Cohort 2
OM
(N = 99)
Cohort 3
OM
(N = 101)
Death 10 (3.3) 8 (2.6) 1 (1.0) 4 (4.0) 3 (3.0)
Cardiovascular 10 (3.3) 8 (2.6) 1 (1.0) 4 (4.0) 3 (3.0)
ACS/MI (fatal) 0 1 (0.3) 0 0 1 (1.0)
All Rehospitalisations 37 (12.2) 29 (9.6) 11 (10.7) 11 (11.1) 7 (6.9)
Acute MI 1 (0.3) 1 (0.3) 1 (1.0) 0 0
Unstable angina 0 0 0 0 0
Heart failure 19 (6.3) 22 (7.3) 6 (5.8) 11 (11.1) 5 (5.0)
Other 18 (5.9) 7 (2.3) 4 (3.9) 0 3 (3.0)
All Index hospitalisation MI (non-fatal) 2 (0.7) 5 (1.7) 1 (1.0) 0 4 (4.0)
Investigator reported 0 (0.0) 2 (0.7) 0 (0.0) 0 2 (2.0)
Troponin triggered 2 (0.7) 3 (1.0) 1 (1.0) 0 2 (2.0)
Total MIs
(Fatal + Rehosp + Nonfatal Index Hosp)
3 (1.0) 7 (2.3) 2 (1.9) 0 5 (5.0)
Post-Randomization Adjudicated Events
ACS/MI = Acute Coronary Syndrome/Myocardial Infarction. 66 patients had 73 positively adjudicated rehospitalisations.

20. Troponin-I Change from Baseline (ng/mL)
Compared with Pooled Placebo
Baseline TnI (ng/mL)
Pooled
Placebo Cohort 1 Cohort 2 Cohort 3
Median 0.044 0.060 0.044 0.056
(Q1, Q3) 0.023, 0.080 0.028, 0.141 0.030, 0.084 0.026, 0.092
4 hours 15 hours 24 hours 48 hours Day 4 Day 6
Time
TroponinChangefromBaseline(ng/mL)
Q3
Median
Q1
0.03
0.02
0.01
0.00
–0.01
–0.02
–0.03
–0.04
–0.05

21. Omecamtiv Mecarbil Concentrations vs.
Troponin-I Maximal Change from Baseline
Red lines represent
linear regression line
and its +/- SE.
Baseline troponin-I
is adjusted.
Omecamtiv mecarbil Cmax Omecamtiv mecarbil AUC0-48
p=0.83p=0.95
MaxTroponin
ChangefromBaseline(ng/mL)
MaxTroponin
ChangefromBaseline(ng/mL)
OM Cmax (ng/mL)
OM Cmax (ng/mL)
OM AUC0-48 (ng*hr/mL)
OM AUC0-48 (ng*hr/mL)
0 200 400 600 800 1000 1200 1400
-40
-20
0
20
40
60
80
100
0 200 400 600 800 1000 1200 1400
-4
-2
0
2
4
0 10000 20000 30000 40000
-40
-20
0
20
40
60
80
100
0 10000 20000 30000 40000
-4
-2
0
2
4

22. Adverse Events (AEs),
Patient Incidence, n (%)
Pooled
Placebo
(N = 303)
Pooled
OM
(N = 303)
Cohort 1
OM
(N = 103)
Cohort 2
OM
(N = 99)
Cohort 3
OM
(N = 101)
All AEs 187 (61.7) 175 (57.8) 73 (70.9) 49 (49.5) 53 (52.5)
3 most common AEs
Cardiac Failure* 53 (17.5) 46 (15.2) 17 (16.5) 14 (14.1) 15 (14.9)
Hypokalaemia 18 (5.9) 20 (6.6) 7 (6.8) 7 (7.1) 6 (5.9)
Hypotension 14 (4.6) 24 (7.9) 14 (13.6) 5 (5.1) 5 (5.0)
Serious AEs 69 (22.8) 66 (21.8) 24 (23.3) 24 (24.2) 18 (17.8)
3 most common serious AEs
Cardiac Failure* 29 (9.6) 26 (8.6) 8 (7.8) 11 (11.1) 7 (6.9)
Renal Failure Acute 4 (1.3) 6 (2.0) 2 (1.9) 2 (2.0) 2 (2.0)
Hypotension 0 (0.0) 3 (1.0) 3 (2.9) 0 (0.0) 0 (0.0)
Deaths 11 (3.6) 9 (3.0) 2 (1.9) 4 (4.0) 3 (3.0)
AEs leading to discontinuation of IP 15 (5.0) 15 (5.0) 7 (6.8) 4 (4.0) 4 (4.0)
Adverse Events
N = Number of patients in the analysis set; IP = Investigational Product.
*
Cardiac failure includes both “Cardiac failure” and “Cardiac Failure Congestive” Preferred Terms.

23. PK/PD Substudy Endpoint:
Change in Systolic Ejection Time (SET)
PK Concentration Bin Analysis Control
OM
Concentration
Bin 1
OM
Concentration
Bin 2
OM
Concentration
Bin 3
OM concentration range (ng/ml) ≥88-200 >200-300 >300-787
Change in SET (msec)
N(n) 45 (88) 10 (18) 15 (23) 12 (19)
LS mean -6.7 16.6 26.9 46.4
Difference from control 23.4 33.6 53.2
95% CI (7.4, 39.4) (19.8, 47.4) (38.0, 68.3)
p-value 0.005 <0.0001 <0.0001
Linear regression slope p < 0.0001
Baseline systolic ejection time for all patients was 258 msec. N: number of patients in the bin,
n: number of observations in the bin; Control = observations in Placebo + PK below quantification
limit; PK bin concentration analysis: repeated measures analysis of covariance; Linear regression
slope analysis: repeated measures multiple linear regression.

24. Change in Heart Rate and SBP
PK Concentration Bin Analysis Control OM Conc. Bin 1 OM Conc. Bin 2 OM Conc. Bin 3
OM concentration range (ng/ml) ≥88-200 >200-300 >300-787
Heart Rate (beats/min)
LS means -4.3 -4.4 -6.3 -6.5
Difference from control -0.1 -2.0 -2.3
95% CI (-1.4, 1.1) (-3.6, -0.4) (-3.9, -0.6)
p-value 0.835 0.016 0.008
Linear regression slope p < 0.0001
SBP (mmHg)
LS means -4.6 -4.4 -4.0 -2.2
Difference from control 0.3 0.6 2.4
95% CI (-1.2, 1.7) (-1.2, 2.4) (0.6, 4.2)
p-value 0.719 0.521 0.009
Linear regression slope p = 0.0017
N: number of patients in the bin, n: number of observations in the bin. Heart rate measured by
ECG. Control = observations in Placebo + PK below quantification limit. PK bin concentration
analysis: repeated measures analysis of covariance. Linear regression slope analysis: repeated
measures multiple linear regression.

25. • Efficacy
– OM did not meet the 1° endpoint of dyspnoea relief
– Appeared to improve dyspnoea in Cohort 3
– Trends towards reduction of worsening HF
• Safety
– Overall SAE profile and tolerability similar to placebo
– Increase in troponin; no clear relationship to OM concentration
– Numerical imbalance in MIs in Cohort 3
– No evidence of pro-arrhythmia
• Pharmacology
– PK similar to healthy volunteers and stable HF patients
– Systolic ejection time significantly increased consistent with MOA
– Small fall in heart rate & rise in systolic BP at higher doses
Summary

26. • Executive Committee:
– Michael Felker
– John McMurray
– John Teerlink (Chair)
• Steering Committee:
– John Cleland
– Kenneth Dickstein
– Justin Ezekowitz
– Gerasimos Filippatos
– Marco Metra
– Piotr Ponikowski
Committees
• Data Monitoring Committee:
– Henry Dargie
– Barry Greenberg
– James Januzzi (Advisor)
– Julie Johnson (Advisor)
– Marv Konstam (Chair)
– Joseph Massaro
– Barry Massie

27. Investigators
Joanna Szachniewicz, Mikhail Kotelnikov, Zhanna Kobalava, Jindrich Spinar, Veselin Mitrovic, Janos
Tomcsanyi, Bela Merkely, Dinesh Gupta, Mason Weiss, Kalman Toth, Pranas Serpytis, Andrzej Wysokinski,
Alain Cohen Solal, Kirkwood Adams, Michel Galinier, Gintare Sakalyte, Hans Vandekerckhove, Fedya
Nikolov, Marco Metra, Steven Krueger, Boycho Boychev, Eustathios Iliodromitis, Ioannis Nanas, Jooyoung
Shin, Javed Butler, Petar Lazov, Guy Proulx, Gaetano De Ferrari, Dmitry Zateyshchikov, Ivan Gordeev, Boris
Goloshchekin, Peter MacDonald, Borislav Atzev, Assen Goudev, Jan Belohlavek, Kumudha Ramasubbu, Nina
Shehova-Iankova, Haissam Haddad, Richard Isnard, Kenneth Dickstein, Jadwiga Nessler, Svetlana Boldueva,
Glenn Hamroff, John Morrow, Lynne Wagoner, Jiri Vitovec, Jans Stevlik, Stephen Gottlieb, Frank McGrew,
Arthur Eberly, Thao Huynh, Henning Ebelt, Thomas Heitzer, Panagiotis Vardas, Dirk Lok, Sergey Tereshenko,
Nina Novikova, Marian Hranai, Debra Weinstein, Eugene Chung, David Lanfear, Denise Barnard, Chetan
Patel, Mark Dunlap, James Maher, Inder Anand, Marc Vanderheyden, Michel de Ceuninck, Ditmar Raev,
Robert Stewart, Pavel Cervinka, Angelika Costard-Jäckle, Athanasios Manolis, Jaroslaw Kasprak, Vladimir
Simanenkov, David Smull, Mitchell Saltzberg, Peter McCullough, Andrew Wilson, Filip Charlier, Serge
Lepage, Justin Ezekowitz, Gordon Moe, Manohara Senaratne, David Zemanek, Pascal De Groote, Rémi
Sabatier, Christian Hengstenberg, Tim Schäufele, Andreas Zeiher, Stephan Felix, Dimitrios Alexopoulos, Bela
Herczeg, Laszlo Zoltan, Eelko Ronner, Wlodzimierz Musial, Piotr Jankowski, Eugeny Shlyakhto, Tatyana
Novikova, Elena Vasilieva, Arsenio Rodriguez, John Teerlink, Alexander Adler, Andrew McRae, Garrie Haas,
Daniel Lenihan, Henry Krum, Carmine De Pasquale, Dariusz Korczyk, Aleksandra Bankova, Stefan Denchev,
Debra Isaac, John David Parker, Veli-Pekka Harjola, Heikki Ukkonen, François Roubille, Gérald Roul, Michael
Böhm, Ruth Strasser, Sebastian Maier, Gerhard Cieslinski, Hans-Georg Olbrich, Noemi Nyolczas, Maurizio
Porcu, Claudio Fresco, Folkert Asselbergs, Lars Gullestad, Andrzej Rynkiewicz, Grigory Aroutiounov, Daniel
Pella, Jozef Kaluzay, John Cleland, Hugh Bethell, Angus Nightingale, John McMurray, Philip Adamson, Todd
Kovach, Jalal Ghali, Andrew Keller, Adrian Van Bakel, James Mudd, Gregory Ewald, Stephanie Dunlap,
Edward McMillan, Freidoon Ghazi, Glenn Barquet, Joshua Larned, Rami Alharethi